Sign in to continue:

Wednesday, May 6th, 2026

Interparfums Inc. Reports Record Q1 2026 Results: $345M Sales, EPS $1.35, Reaffirms Guidance and Dividend




Inter Parfums, Inc. Reports Record Q1 2026 Results – Key Takeaways for Investors

Inter Parfums, Inc. Delivers Record First Quarter 2026 Results: Key Insights for Investors

New York, May 5, 2026 – Inter Parfums, Inc. (NASDAQ GS: IPAR) has announced record-breaking financial results for the first quarter ended March 31, 2026, reaffirming its full-year guidance and declaring a quarterly dividend. The company’s robust performance is highlighted by significant growth in core brands, resilience amidst global challenges, and continued commitment to shareholder returns.

Key Financial Highlights

  • Net Sales: \$345 million, up 2% from \$339 million in Q1 2025.
  • Gross Margin: 65.1%, up 140 basis points year-over-year.
  • Operating Income: \$74 million, slightly down from \$75 million in Q1 2025.
  • Operating Margin: 21.5%, compared to 22.2% last year.
  • Net Income attributable to Inter Parfums, Inc.: \$43 million, up 2% from \$42 million.
  • Diluted EPS: \$1.35, compared to \$1.32 last year.
  • Foreign Exchange Impact: Positive 4.6% due to a higher average dollar/euro exchange rate (1.17 vs 1.05).
  • Strong Cash Position: \$237 million in cash, cash equivalents, and short-term investments; working capital of \$692 million.
  • Dividend: Quarterly cash dividend of \$0.80 per share, payable June 30, 2026 (record date June 15, 2026).

Operational Highlights and Geographic Performance

  • United States and European Operations: Both segments delivered year-over-year growth, underscoring the resilience and appeal of the company’s brands.
  • North America: Sales rose by 7%, driven by market growth and successful new product launches, particularly for Coach.
  • Central and South America: Sales surged by 23% on the strength of Coach and Montblanc Legend.
  • Western Europe: Sales remained flat due to slow consumer demand.
  • Eastern Europe: Sales declined, mainly due to operational difficulties affecting Lanvin and Lacoste.
  • Middle East and Africa: Declines attributed to regional conflicts and wars.
  • Asia/Pacific: Lower sales due to distribution changes in South Korea and India and weaker demand in Australia/New Zealand, partially offset by strong growth in China.

Brand Performance

  • Coach: Sales up 30%, leading the portfolio.
  • Montblanc: Up 14%.
  • GUESS: Up 11%.
  • Roberto Cavalli: Up 32%.
  • Jimmy Choo: U.S. sales grew, but global net sales declined 4% due to downturns in Europe and Asia.
  • Lacoste: Down 12%, after a strong prior-year comparison and weaker Eastern Europe conditions.
  • Donna Karan/DKNY: Down 3%, but “Be Delicious Core” rebounded by 16%.

Strategic Initiatives & New Launches

  • New Line Extensions (2026): Across multiple brands, including Jimmy Choo Man Parfum, Coach Cherry (women) and Platinum (men), Montblanc Legend Elixir, GUESS Iconic Suede, Lacoste Original Aqua, Donna Karan/DKNY Cashmere & Rose Absolu, Roberto Cavalli Uorde Assoluto.
  • Pipeline: More extensions and major launches planned for 2027, including Ferragamo.

ESG Progress

  • ESG Rating: Inter Parfums received its third consecutive MSCI ESG rating upgrade, now at BBB, reflecting improved risk management for environmental and social issues.

Financial Commentary and Shareholder Considerations

  • Gross Margin Expansion: Up 140 basis points due to favorable product and channel mix and lower destruction costs, partially offset by tariffs.
  • SG&A Expenses: Rose to 43.6% of net sales (from 41.6%), primarily due to higher royalty and logistics costs.
  • Operating Income: Slightly lower, but offset by improved other income (gain of \$1.1 million vs. a \$1.7 million loss last year).
  • Tax Rate: Stable at 24.6%.
  • Inventory Days on Hand: Improved by 17 days to 259 days, reflecting operational efficiencies.
  • Long-Term Debt: Approximately \$157 million.

Outlook and Guidance

  • 2026 Guidance Reaffirmed: Sales target of \$1.48 billion and EPS of \$4.85, assuming stable dollar/euro exchange rates.
  • Management’s Position: Confident in navigating short-term volatility and committed to long-term value creation, while closely monitoring global risks (Middle East conflicts, inflation, tariffs).
  • Dividend Policy: Maintains quarterly dividend of \$0.80 per share.

Conference Call Details

Management will host a conference call to discuss results and outlook at 11:00 am ET, Wednesday, May 6, 2026.
Dial-in: U.S. (877) 423-9820, International (201) 493-6749.
A webcast replay will be available for 90 days on the company’s investor relations website.

Investor Takeaways & Potential Share Price Drivers

  • Positive: Record Q1 sales and net income, gross margin expansion, and robust brand and geographic performance could be viewed as bullish for the share price.
  • Positive: Reaffirmed full-year guidance and continued dividend payments demonstrate management’s confidence in the business.
  • Neutral/Watch: Some pockets of weakness (Eastern Europe, Middle East, and Asia) and elevated SG&A expenses may warrant monitoring, but these are offset by gains in core markets and brands.
  • Positive: Strong cash position, efficient inventory management, and reductions in long-term debt support financial stability and potential for future shareholder returns.
  • Positive: Continued ESG improvements and successful new product launches strengthen long-term brand equity and risk profile.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review the company’s official filings and consult with a qualified financial advisor before making investment decisions.




View INTERPARFUMS INC Historical chart here



CLIMB BIO, INC. 2025 Annual Report: Business Overview, Risk Factors, Strategy, and Financials (Form 10-K)

Climb Bio, Inc. 2025 Annual Report: Key Highlights & Shareho...

ANI Pharmaceuticals, Inc. Files Form 8-K Announcing Auditor Change – April 2026 SEC Filing Details

ANI Pharmaceuticals, Inc. Announces Change in Independent Au...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today